FOIA requests to the federal government often are signals. They can be an important early warning of bad publicity, litigation to come, or uncertainties to be hedged and gamed out. When the flow of ...

El Lilly’s (LLY) blockbuster weight-loss drug Zepbound is now eligible for Medicare coverage. The news could significantly ...

Eli Lilly's (NYSE:LLY) weight-loss drug Zepbound is now reportedly covered by Medicare for the treatment of obstructive sleep ...

Hello, Health Rounds Readers! Today we feature a study that found yet another potential health benefit of GLP-1 drugs, this ...

Eli Lilly's Tirzepatide Outshines Novo Nordisk's Semaglutide, Yet Brand Recognition Remains Strong for Novo's Products ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 484.89% and ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

The U.S. FDA has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea.

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

Eli Lilly joins FDA lawsuit over tirzepatide shortage listing, as Outsourcing Facilities Association challenges removal of ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

An Eli Lilly spokesperson said in a statement that the company was pleased that regulators in Tennessee took action to “stop one of the bad actors selling knockoff tirzepatide.” Lilly has ...